American CryoStem Corporation (CRYO)
American CryoStem Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Eatontown, NJ, US. The stock last traded at $0.00, down 99.75% on the session, giving a market capitalisation of $4,428. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -13985.4%. Its beta of 11.42 implies it has historically moved more than the broad market.
American CryoStem Corporation (ACSC) specializes in the development, commercialization, and licensing of technologies derived from adipose (fat) tissue, primarily for applications within regenerative and personalized medicine. Among its key offerings is the CELLECT system, designed to streamline tissue sample collection, transportation, and storage for medical practitioners. The company also provides the ATGRAFT service, a comprehensive solution for harvesting, processing, and preserving adipose tissue, enabling physicians to offer patients versatile options for tissue products and cellular banking. Complementing these are ATCELL, a line of proprietary adipose-derived stem cells, and ACSelerat cell culture media, specifically formulated to promote the growth of human stromal cells. Furthermore, American CryoStem extends its expertise through contract manufacturing services for specific formulations, including Autokine-CM, an anti-aging topical product, and a unique autologous skin care range. Founded in 1987, American CryoStem Corporation is headquartered in Eatontown, New Jersey.
American CryoStem Corporation is most often compared with the following Healthcare names: